Cormac McGrady is a Private Equity Associate in Weil’s London office. He advises sponsor clients and other institutional investors on a wide range of complex secondary transactions.
Cormac regularly acts on both buy side and sell side on the full spectrum of secondaries transactions including GP-led secondaries/continuation fund transactions, preferred equity investments and traditional LP portfolio transactions. In addition, Cormac also advises GP stake investors on the acquisition and disposition of stakes in fund managers.
Cormac also has experience advising private equity sponsors and their portfolio companies on a wide range of domestic and multi-jurisdictional M&A transactions.
Representative experience as part of a team, including prior to joining Weil, includes:
- HarbourVest Partners as a lead investor on its investment in Inflexion’s £2.3 billion multi-asset continuation fund which, at the date of closing, was the largest multi-asset continuation fund raised in Europe to date
- Sovereign investors and large institutional investors on structuring, negotiation and documentation of all stages of secondary transactions, including GP-led recapitalizations, secondary purchases and sales, and other structured liquidity transactions
- Regularly advising sovereign investors and other institutional investors (including pension funds) in co-investment transactions
- Bain Capital on its sale of the Zellis group to Apax Partners, valuing Zellis at £1.25 billion
- Funds advised by Permira on their approximately $5.8 billion acquisition of Mimecast
- AEA Investors on its sale of a majority stake in Scan Global Logistics as part of a deal valued at approximately $1.5 billion
- Liberty Global Ventures on its joint venture arrangements with InfraVia Capital Partners in connection with greenfield development of fibre-to-the-home (FTTH) broadband infrastructure across certain underserved German municipalities
- Francisco Partners on its sale of LiveU to funds advised by the Carlyle Group
- Funds advised by Clayton, Dubilier & Rice, LLC on the £2.8 billion acquisition of UDG Healthcare
- Fenergo Limited and its shareholders on its sale to funds advised by Bridgepoint and Astorg